XBP1 and hematopoietic and lymphoid system neoplasm: Of note, the FDA-approved anticancer drug sunitinib inhibits IRE1α autophosphorylation, diminishing XBP1 splicing in blood cancer cells treated with an ER stress inducer [15,204].